A Novel Synchronous Estimation of Metronidazole, Ciprofloxacin and Doxycycline by RP-HPLC in Bulk and Pharmaceutical Formulation

Rama Rao Nadendla a*, Siva Prasad Morla a, Abhinandana Patchala a and Prachet Pinnamaneni a

a Chalapathi Institute of Pharmaceutical Sciences, Lam, Guntur-522034, Andhra Pradesh, India.

Authors’ contributions
This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information
DOI: 10.9734/JPRI/2021/v33i53A33670
Editor(s):
(1) Dr. Rafik Karaman, Al-Quds University, Palestine.
Reviewers:
(1) Rasha Moustafa Youssef, Alexandria University, Egypt.
(2) Prabhakar S. Panzade, Srinath College of Pharmacy, India.
Complete Peer review History, details of the editor(s), Reviewers and additional Reviewers are available here:
https://www.sdiarticle5.com/review-history/66154

Received 10 December 2020
Accepted 22 February 2021
Published 06 December 2021

ABSTRACT

Aim: To design simple, rapid, new analytical method for estimation of Metronidazole, Ciprofloxacin Doxycycline by using RP-HPLC in bulk and pharmaceutical dosage form.

Study Design: Estimation of Metronidazole, Ciprofloxacin Doxycycline by using RP-HPLC in bulk and pharmaceutical dosage form was planned and executed.

Place and Duration of Study: Chalapathi Drug Testing Laboratory, Chalapathi Institute Of Pharmaceutical Sciences, Lam, Guntur-522034, Andhra Pradesh, India during the period of November 2019 to February 2020.

Methodology: Metronidazole is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis and bacterial vaginosis. Ciprofloxacin is an antibiotic used to treat a number of bacterial infections. Doxycycline is a tetracycline antibiotic that fights bacteria in the body. The study was carried out on SHIMADZU Prominance-i, LC-2030C system equipped with Shim-pack Gist (250 x 4.6 mm, 5μm) column and mobile phase was optimized by using mixture of methanol and 0.25M potassium phosphate buffer in the ration of 60:40 v/v at a flow rate of 0.8 ml/min. The wavelength was set as 282nm at ambient temperature by injecting 20μl of solution and the run time was fixed for 10 min.
Results: Linearity plot was constructed for concentration range of 5-15µg/ml for Metronidazole, 5-15µg/ml for Ciprofloxacin and 1-8µg/ml for Doxycycline standard solutions. It shows best regression coefficient and y/s values. The accuracy of the proposed method was determined by performing recovery studies and was found between 98-102%. The repeatability testing for both sample and standard solutions the %RSD was found as <2.0% which is within the acceptable limits showing that the method is precise as well. The LOD and LOQ were found to be 0.33 and 0.99 µg/ml for Metronidazole, 0.08 and 0.25 µg/ml for Ciprofloxacin, 0.08 and 0.25 µg/ml for Doxycycline respectively. The proposed method was successfully applied for the pharmaceutical dosage form of Metronidazole, Ciprofloxacin Doxycycline and it was as economic, eco-friendly with less retention time around 10.0 min.

Conclusion: The proposed method was validated in terms of linearity, range, Accuracy, precision, Specificity, Robustness. Method was successfully applied to the estimation of Metronidazole, Ciprofloxacin Doxycycline in combined marketed pharmaceutical dosage form.

Keywords: Metronidazole; ciprofloxacin; doxycycline; pharmaceutical formulation.

1. INTRODUCTION

Metronidazole is an antibiotic and antiprotozoal medication. It is used either alone or with other antibiotics to treat pelvic inflammatory disease, endocarditis and bacterial vaginosis [1-4]. The chemical name is 2-(2-methyl-5-nitro-1H-imidazol-1-yl) ethan-1-ol. Literature survey revealed that only few methods were reported for estimation of Metronidazole by RP- HPLC [5-7].

Fig. 1. Chemical structure of metronidazole

Ciprofloxacin is an antibiotic used to treat a number of bacterial infections. This includes bone and joint infections, intra abdominal infections, certain type of infectious diarrhea, respiratory tract infections, skin infections, typhoid fever and urinary tract infections, among others [8-11]. For some infections it is used in addition to other antibiotics. It can be taken by mouth, as eye drops, as ear drops, or intravenously. Its chemical name is 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid.

Fig. 2. Chemical structure of ciprofloxacin

Doxycycline is a tetracycline antibiotic that fights bacteria in the body. Doxycycline is used to treat many different bacterial infections, such as acne, urinary tract infections, intestinal infections, respiratory infections, eye infections, gonorrhea, chlamydia, syphilis, periodontitis and others [12-15]. There is no proved analytical method in combined dosage form was found by going through the literature.

Fig. 3. Chemical Structure of Doxycycline

2. MATERIALS AND METHODS

2.1 Chemicals and Reagents

Gland pharma limited Ltd, Hyderabad, India kindly supplied the pure working standards of known potency of Metronidazole, Ciprofloxacin Doxycycline as gift samples. The reagents like
2.2 Instrumentation

The HPLC system consists of Shimadzu Prominence-I, LC-2030C series HPLC consisting of quaternary pump, Auto sampler, Auto injector & photo diode array detector, thermostatic column compartment connected with lab solutions software with a Shim-pack GIST C<sub>18</sub> (250 × 4.6 mm, 5µ) column.

2.3 Preparation of Standard Solution

Accurately weighed 10 mg of each drug transferred into different 10 ml volumetric flasks add 6 ml of diluent and sonicated for 15 min to dissolve compound and volume made up with diluent to 10 ml. Further the concentrations of 10 µg/ml, 10 µg/ml, 4 µg/ml of Metronidazole, Ciprofloxacin Doxycycline were prepared.

2.4 Preparation of Sample Solution

Accurately weighed one tablet equivalent powder and transferred into 250 ml volumetric flask dissolved in diluent and sonicated for 30 mins, the volume was made up with diluent, filtered with 0.45 µ PVDF filter. Further 1 ml diluted 100 ml with diluent.

2.5 Optimazation of HPLC Methods

The HPLC method was optimized with Shimadzu Prominence-I, LC-2030C series HPLC consisting of quaternary pump, Auto sampler, Auto injector & photo diode array detector, thermostatic column compartment connected with lab solutions software and column Shim-pack GIST C<sub>18</sub> (250 × 4.6 mm, 5µ). Mobile phase 0.025 M potassium phosphate buffer and methanol in 70:30 v/v ratio used. The flow rate of the mobile phase was maintained at 0.8 mL/min and the detection was carried out at 260 nm with an injection volume of 20 µl.

3. RESULTS AND DISCUSSION

After RP-HPLC method development is completed, validation was performed for following parameters.

3.1 System Suitability

System suitability test is performed to determine the suitability and effectiveness of chromatographic system. Chromatographic parameters such as the number of theoretical plates, resolution, asymmetry, detection limit and selectivity were taken into consideration. Standard solution of 10 µg/ml, 10 µg/ml, 4 µg/ml Metronidazole, Ciprofloxacin Doxycycline was prepared and injected into HPLC system and. Observed results were tabulated in Table no. 1.
| S.No | Injection number | Peak area for Metronidazole | Peak area for Ciprofloxacin | Peak area for Doxycycline | Acceptance criteria |
|------|------------------|-----------------------------|-----------------------------|---------------------------|-------------------|
| 1    | 01               | 476958                      | 1412528                     | 84472                     | The % RSD of peak areas should not be more than 2.0. |
| 2    | 02               | 477256                      | 1411954                     | 84859                     |                   |
| 3    | 03               | 475691                      | 1414368                     | 84762                     |                   |
| 4    | 04               | 477658                      | 1413568                     | 84389                     |                   |
| 5    | 05               | 476658                      | 1418456                     | 84581                     |                   |
| 6    | 06               | 477258                      | 1416189                     | 84656                     |                   |
| Mean |                  | 476913                      | 1414511                     | 84620                     |                   |

| %RSD | 0.14 | 0.17 | 0.21 | |

### Table 1. System suitability data

**Table 2. Intra-day precision for metronidazole, ciprofloxacin and doxycycline**

| S.NO | Injection number | Peak area for Metronidazole | Peak area for Ciprofloxacin | Peak area for Doxycycline |
|------|------------------|-----------------------------|-----------------------------|---------------------------|
| 1    | 1                | 476884                      | 1415825                     | 84514                     |
| 2    | 2                | 476985                      | 1415256                     | 84672                     |
| 3    | 3                | 476879                      | 1414576                     | 84126                     |
| 4    | 4                | 478148                      | 1415487                     | 84681                     |
| 5    | 5                | 476258                      | 1416458                     | 84574                     |
| 6    | 6                | 477369                      | 1417258                     | 84584                     |
| Mean |                  | 477087                      | 1415810                     | 84525                     |

| %RSD | 0.13 | 0.07 | 0.24 | |

### Table 3. Inter-day precision for metronidazole, ciprofloxacin and doxycycline

| S.NO | Injection number | Peak area for Metronidazole | Peak area for Ciprofloxacin | Peak area for Doxycycline |
|------|------------------|-----------------------------|-----------------------------|---------------------------|
| 1    | 1                | 478416                      | 1411968                     | 84567                     |
| 2    | 2                | 475964                      | 1418569                     | 84897                     |
| 3    | 3                | 476268                      | 1413895                     | 84685                     |
| 4    | 4                | 478562                      | 1416895                     | 84789                     |
| 5    | 5                | 477826                      | 1417259                     | 84562                     |
| 6    | 6                | 476859                      | 1418468                     | 84656                     |
| Mean |                  | 477316                      | 1416176                     | 84693                     |

| %RSD | 0.23 | 0.19 | 0.15 | |

### Table 4. Report of LOD and LOQ

| S.NO | Drugs     | LOD (µg/ml) | LOQ (µg/ml) |
|------|-----------|-------------|-------------|
| 1    | Metronidazole | 0.33        | 0.99        |
| 2    | Ciprofloxacin | 0.33        | 0.99        |
| 3    | Doxycycline  | 0.08        | 0.25        |
Table 5. Report of linearity

| Standard Conc(µg/ml) | Area of Metronidazole | Standard Conc(µg/ml) | Area of Ciprofloxacin | Standard Conc(µg/ml) | Area of Doxycycline |
|----------------------|-----------------------|----------------------|-----------------------|----------------------|---------------------|
| 5                    | 238463                | 5                    | 743057                | 1                    | 21040               |
| 7.5                  | 357694                | 7.5                  | 1077808               | 2                    | 41080               |
| 10                   | 476925                | 10                   | 1410013               | 4                    | 84160               |
| 12.5                 | 586156                | 12.5                 | 1798654               | 6                    | 125240              |
| 15                   | 711388                | 15                   | 2097774               | 8                    | 168720              |

Fig. 5. Calibration curve of Doxycycline

\[ y = 20746x + 211.23 \]
\[ R^2 = 0.9998 \]

Fig. 6. Calibration curve of Metronidazole

\[ y = 47224x + 1571.6 \]
\[ R^2 = 0.9998 \]

Fig. 7. Calibration curve of ciprofloxacin

\[ y = 140260x + 19053 \]
\[ R^2 = 0.9992 \]
Table 6. Accuracy data

| Level | Peak area | % recovery | Mean % recovery | Over all recovery |
|-------|-----------|------------|----------------|------------------|
|       | Met       | CIP        | Doxy           | Met              | CIP             | Doxy           | Met  | CIP | Doxy |
| 50    | 238547    | 715264     | 42576          | 99.72            | 100.50          | 100.01         | 100.14 | 100.12 | 100.16 |
|       | 239261    | 711854     | 42651          | 100.11           | 100.12          | 100.48         |       |      |      |
| 100   | 477021    | 1412856    | 84589          | 99.87            | 99.43           | 99.71          | 99.73 | 99.81 | 99.87 |
|       | 476924    | 1411965    | 84750          | 99.83            | 99.35           | 99.88          |       |      |      |
|       | 475298    | 1430589    | 84890          | 99.48            | 100.65          | 100.03         |       |      |      |
| 150   | 721895    | 2120456    | 126842         | 100.73           | 99.45           | 99.65          | 100.69 | 100.29 | 100.05 |
|       | 721245    | 2152321    | 127891         | 100.65           | 100.96          | 100.48         |       |      |      |
|       | 721516    | 2141598    | 127296         | 100.70           | 100.47          | 100.03         |       |      |      |

Table 7. Report of robustness – metronidazole

| S.No. | Parameter                        | Condition   | % RSD | USP tailing | USP plate count |
|-------|----------------------------------|-------------|-------|-------------|-----------------|
| 1     | Flow rate by ± 2%                 | 1.0 ml      | 0.94  | 0.99        | 6878            |
|       |                                  | 0.8 ml      | 0.74  | 1.05        | 6695            |
|       |                                  | 0.6 ml      | 0.65  | 1.01        | 6308            |
| 2     | Column oven temperature by ± 2°C | 23°C         | 0.28  | 1.02        | 6603            |
|       |                                  | 25°C         | 0.19  | 1.11        | 6256            |
|       |                                  | 27°C         | 0.45  | 1.23        | 6968            |
| 3     | Wavelength of analysis ± 2nm      | 280 nm       | 0.59  | 1.10        | 6965            |
|       |                                  | 282 nm       | 0.66  | 1.14        | 6664            |
|       |                                  | 284 nm       | 0.80  | 1.01        | 6723            |
| 4     | Organic composition of mobile phase by ± 5% | 65:35       | 0.29  | 1.23        | 6527            |
|       |                                  | 70:30        | 0.45  | 1.14        | 6692            |
|       |                                  | 75:25        | 0.65  | 1.12        | 6052            |
### Table 8. Report of robustness – ciprofloxacin

| S.No. | Parameter                          | Condition | % RSD | USP tailing | USP plate count |
|-------|------------------------------------|-----------|-------|-------------|-----------------|
| 1     | Flow rate by ± 2%                  | 1.0 ml    | 0.45  | 1.21        | 7638            |
|       |                                    | 0.8 ml    | 0.24  | 1.23        | 7410            |
|       |                                    | 0.6 ml    | 0.19  | 1.10        | 7308            |
| 2     | Column oven temperature by ± 2°C   | 23°C      | 0.78  | 1.24        | 7603            |
|       |                                    | 25°C      | 0.65  | 1.22        | 7850            |
|       |                                    | 27°C      | 0.44  | 1.14        | 7652            |
| 3     | Wavelength of analysis ± 2nm       | 280 nm    | 0.21  | 0.91        | 7921            |
|       |                                    | 282 nm    | 0.32  | 0.96        | 7652            |
|       |                                    | 284 nm    | 0.71  | 0.86        | 7121            |
| 4     | Organic composition of mobile phase by ± 5% | 65:35 | 0.69 | 1.23        | 7542            |
|       |                                    | 70:30     | 0.58  | 1.16        | 7721            |
|       |                                    | 75:25     | 0.72  | 1.19        | 7533            |

### Table 9. Report of robustness – doxycycline

| S.No. | Parameter                          | Condition | % RSD | USP tailing | USP plate count |
|-------|------------------------------------|-----------|-------|-------------|-----------------|
| 1     | Flow rate by ± 2%                  | 1.0 ml    | 0.18  | 1.24        | 9531            |
|       |                                    | 0.8 ml    | 0.25  | 1.15        | 9456            |
|       |                                    | 0.6 ml    | 0.15  | 1.04        | 9210            |
| 2     | Column oven temperature by ± 2°C   | 23°C      | 0.22  | 1.32        | 9900            |
|       |                                    | 25°C      | 0.14  | 1.21        | 9533            |
|       |                                    | 27°C      | 0.17  | 1.17        | 9411            |
| 3     | Wavelength of analysis ± 2nm       | 280 nm    | 0.56  | 1.16        | 9865            |
|       |                                    | 282 nm    | 0.72  | 1.21        | 9456            |
|       |                                    | 284 nm    | 0.65  | 1.09        | 9741            |
| 4     | Organic composition of mobile phase by ± 5% | 65:35 | 0.79 | 1.26        | 9648            |
|       |                                    | 70:30     | 0.73  | 1.15        | 9315            |
|       |                                    | 75:25     | 0.75  | 1.11        | 9145            |

### Table 10. Results of assay

| Drug    | Label Claim | %Assay |
|---------|-------------|--------|
| Metronidazole | 250          | 100.14 |
| Ciprofloxacin   | 250          | 100.12 |
| Doxycycline    | 100          | 100.16 |

### 3.2 Precision

Precision can be defined as the degree of agreement among individual test results when the procedure is applied repeatedly to multiple samplings. The relative standard deviation of individual areas of Metronidazole, Ciprofloxacin and Doxycycline were found to be within limits (≥2.0).

#### 3.2.1 Intra-day Precision

The intra-day precision of the assay was estimated by calculating the relative standard deviation (RSD) for the analysis of QC samples in six replicates and inter-day precision was determined by the analysis of six replicates QC samples on three consecutive days.

#### 3.2.2 Inter-day precision

The inter-day precision was determined by the analysis of six replicates QC samples on three consecutive days.

### 3.3 Limit of Detection and Limit of Quantization

Limit of Detection (LoD) and Limit of Quantitation (LoQ) are terms used to describe
the less concentration of a measurand that can be reliably measured by an analytical procedure.

3.4 Linearity

Linearity is the method’s ability to obtain test results which are directly proportional to the concentration of analyte in the sample. A series of standard solutions were prepared in the range of 5 µg/ml-15 µg/ml for Metronidazole, Ciprofloxacin and Doxycycline in range for 1µg/ml-8µg/ml. The mixture of standard solutions was injected into HPLC system and calculated the correlation coefficient value, Y-intercept for area and concentrations of the standard injected.

3.5 Accuracy

To determine the Accuracy of the proposed method, recovery studies were conducted. The known amount of pure drug concentrations were spiked in three different levels which were 50%, 100% and 150% and accuracy was calculated and tabulated below in Table 6.

3.6 Robustness

Robustness of the proposed method demonstrated a non-significant alteration through analysis of the sample and standard Metronidazole, Ciprofloxacin and Doxycycline solution (Table 7). The results obtained were compared with that of optimized method. It was confirmed that by making the deliberate changes in the parameters there were no significant changes in standard deviation, relative standard deviation, theoretical plates, retention time and USP tailing factor were found.

3.7 Assay Results

Accurately weighed 20 tablets and crushed to fine powder. Accurately weighed powder equivalent to 750 mg and transferred into 250 ml volumetric flask dissolved in diluent and sonicated for 30mins, the volume was made up with diluent, filtered with 0.45µ PVDF filter. Further 1ml diluted 100ml with diluent.

4. CONCLUSION

A simple, specific and reliable isocratic HPLC-PDA method was developed for the estimation of Metronidazole, Ciprofloxacin and Doxycycline in their bulk and pharmaceutical formulation was given. The current method was validated according to Q2 (R1) ICH guidelines in terms of Linearity, Accuracy, Precision, Limit of detection, Limit of quantification and Robustness. Linearity plot was constructed for concentration range of 5-15 µg/ml for Metronidazole, 5-15 µg/ml for Ciprofloxacin and 1-8 µg/ml for Doxycycline as standard solutions. It shows best regression coefficient and y/s values. The accuracy of the proposed method was determined by performing recovery studies and was found between 98-102%. The repeatability testing for both sample and standard solutions was found as %RSD<2.0% which is within the acceptable limits showing that the method is precise as well. The LOD and LOQ were found to be 0.33 and 0.99 µg/ml for Metronidazole, 0.33 and 0.99 µg/ml for Ciprofloxacin, 0.08 and 0.25 µg/ml for Doxycycline respectively. Hence the current developed method can be fruitfully applied for the estimation of Metronidazole, Ciprofloxacin and Doxycycline in drug testing laboratories and pharmaceutical industries.

4.1 Novelty of Present Work

As there is no particular combination of these mentioned three drugs, we have formulated one which can be used to treat fungal and bacterial infections and estimated it technically by simultaneous estimation method using RP-HPLC. We Have reported the results in result and discussion section.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.
REFERENCES

1. Khadabadi SS, Meenakshi G, Devkar, et al. A validated rp-hplc method for simultaneous estimation of metronidazole and ciprofloxacin hydrochloride in pharmaceutical dosage form. International Journal Of Pharmaceutical Sciences and Research. 2013;4(12):4736-40. Available:http://dx.doi.org/10.13040/IJPSR.0975-8232.

2. Ghoufran Kawas, Mohammad Marouf, Oussama Mansour, Amir Alhaj Sakur, et al. Analytical methods of ciprofloxacin and its combinations review. Research J. Pharm. and Tech. 2018;11(5):2139-2148. DOI: 10.5958/0974-360X.2018.00396.7

3. Ramzia I. El-Bagary1,2, Asmaa A. El-Zahe1, Ehab F. Elkady1, Maha M. El-Hakim1, Asmaa A. Mandour2,* et al. Stability indicating HPLC method for the simultaneous determination of ciprofloxacin hydrochloride and metronidazole in the presence of ciprofloxacin acid degradation products. Journal of Biochemical and Pharmaceutical Research. 2015;5(1).

4. Agnes Budiartia, Ibnu Gholib Gandjarb, Abdul Rohmanb CD, et al. Liquid chromatography with UV detection for simultaneous determination of ciprofloxacin and metronidazole. JurnalTeknologi; 2014.

5. Available:https://en.wikipedia.org/wiki/Metronidazole
6. Available:https://en.wikipedia.org/wiki/Ciprofloxacin
7. Available:https://en.wikipedia.org/wiki/Doxycline
8. Sani A Ali et al. High performance liquid chromatography (HPLC) method development and validation indicating assay for ciprofloxacin hydrochloride. Journal of Applied Pharmaceutical Science. 2011;01(08):239-243.
9. Neetu Sachan, et al. Novel method for simultaneous estimation of ciprofloxacin hydrochloride and ofloxacin by reverse phase-high performance liquid chromatography (RP-HPLC). International Journal Of Pharmaceutical Sciences And Research, Available:http://dx.doi.org/10.13040/IJPSR.0975-8232.1(7).100-07
10. Rote AR, et al. High performance liquid chromatographic determination of ciprofloxacin hydrochloride and ornidazole in human plasma, pharmaceutical analytical chemistry: Open Access; 2015.
11. Tadele Eticha, et al. Chemometric-assisted spectrophotometric method for the simultaneous determination of ciprofloxacin and doxycycline hyclate in pharmaceutical formulations; 2018.
12. Maslarska V, Tsvetkova B, Peikova L, Kostova B, Rachev D, Bozhanov S, Zareva N. HPLC assay of model tablet formulations containing metronidazole and ciprofloxacin. International Journal of Pharmacy and Pharmaceutical Sciences. 2016;8(5):306-10.
13. Ana Carolina Kogawa, Hérida Regina Nunes Salgado, et al. Quantification of doxycycline hyclate in tablets by HPLC–UV method. Journal of Chromatographic Science, 2013;51(10):919–925.
14. Zoran Ž, Bojanić, et al. HPLC method development for determination of doxycycline in human seminal fluid, Journal of Chromatography B. 2013;939(15):17-22.
15. Yen-Hsia Wen, et al. Analysis of ciprofloxacin by a simple high-performance liquid chromatography method. Journal of Chromatographic Science. 2008;46.